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Background: A pilot project cardiovascular prevention was implemented in Sandwell (West Midlands, UK). This used
electronic primary care records to identify untreated patients at high risk of cardiovascular disease then invited these
high risk patients for assessment by a nurse in their own general practice. Those found to be eligible for treatment
were offered treatment. During the pilot a higher proportion of high risk patients were started on treatment in the
intervention practices than in control practices. Following the apparent success of the prevention project, it was
intended to extend the service to all practices across the Sandwell area. However the pilot project was not a robust
evaluation. There was a need for an efficient evaluation that would not disrupt the planned rollout of the project.
Methods/design: Project nurses will sequentially implement targeted cardiovascular case finding in a phased way
across all general practices, with the sequence of general practices determined randomly. This is a stepped wedge
randomised controlled trial design. The target population is patients aged 35 to 74, without diabetes or cardiovascular
disease whose ten-year cardiovascular risk, (determined from data in their electronic records) is ≥20%. The primary
outcome is the number of high risk patients started on treatment, because these data could be efficiently obtained
from electronic primary care records. From this we can determine the effects of the case finding programme on the
proportion of high risk patients started on treatment in practices before and after implementation of targeted case
finding. Cost-effectiveness will be modelled from the predicted effects of treatments on cardiovascular events and
associated health service costs. Alongside the implementation it is intended to interview clinical staff and patients who
participated in the programme in order to determine acceptability to patients and clinicians. Practical considerations
meant that 26 practices in Sandwell could be randomised, including about 6,250 patients at high risk of cardiovascular
disease. This gives sufficient power for evaluation.
Discussion: It is possible to design a stepped wedge randomised controlled trial using routine data to determine the
primary outcome to evaluate implementation of a cardiovascular prevention programme.
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Cardiovascular disease (CVD) remains the UK’s largest
cause of morbidity and mortality. There is overwhelming
evidence that drug treatment to lower blood pressure
and lipid levels reduce the incidence of and mortality
from CVD. Under UK guidelines, statins are recom-
mended for all high-risk patients and antihypertensive
drugs for those high risk patients if their blood pressure* Correspondence: T.P.Marshall@bham.ac.uk
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reproduction in any medium, provided the oris ≥140/90 mm Hg [1-4]. They also recommend that
patients with familial hypercholesterolaemia are pre-
scribed statins and those whose blood pressure ≥160/
100 mm Hg are prescribed antihypertensives, irrespect-
ive of their risk status [1,3,5]. The guidelines define high
risk as either the presence of atherosclerotic disease or
≥20% predicted ten-year cumulative risk of coronary
heart disease or stroke, using the Framingham equa-
tions.[5] This means that all those at ≥20% ten-year
CVD risk are eligible for statin treatment and many are
eligible for both statin and antihypertensive treatments.
Some guidelines also recommend that individuals atl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, the recommendation is controversial as the
risk benefit ratio in patients taking other preventive
treatments is only marginally favourable [6].
Historically in the UK there have not been systematic
attempts to identify and offer CVD prevention and most
primary prevention of CVD has been undertaken when
patients are identified opportunistically in primary care.
However there may be weaknesses with this approach.
GPs do not always follow guidelines in routine clinical
practice [7]. They may not fully recognise the clinical
importance of statin prescribing and when eligible
patients consult, physicians commonly delay prescribing
decisions until the next visit [8,9]. There is also confu-
sion about which patients are eligible for treatment. In
New Zealand, where risk based hypertension guidelines
were first adopted, clinicians reported they would treat
low risk younger adults at lower blood pressures than
high risk older adults [10]. When deciding whether to
prescribe, GPs also seem to give greater weight to indi-
vidual risk factor values than global risk [11]. In oppor-
tunistic screening CVD risk calculation may also not be
carried out, it may be done incorrectly and it often var-
ies from one physician to another [12-15]. The oppor-
tunistic strategy therefore may not be sufficient and in
the UK, many eligible individuals remain untreated. In
2009, 29% of adults were hypertensive of whom 51%
were untreated and the figures have changed little since
2005 [16].
Recently, the NHS announced a programme of NHS
Health Checks, to be offered to all adults aged 40 to 74
as part of a five year rolling programme to screen
people for CVD and diabetes and offer lifestyle and pre-
ventative advice [17]. Economic modelling suggested
that universal screening, such as that implemented
under the NHS health checks, would be cost effective
[18]. However, the modelling did not explicitly compare
a strategy of universal screening of all those in the
selected age range with case finding targeted at those
most likely to benefit. Furthermore, cost-effectiveness
modelling studies indicate that a strategy of prioritising
untreated patients for assessment on the basis of their
estimated ten-year CVD risk should, in theory, be the
most efficient prevention strategy for untreated patients
[19,20]. This finding has further support from a subse-
quent modelling study using a different multivariable
risk prediction equation [21].
Economic modeling studies therefore suggest that tar-
geted, rather than universal, screening approaches could
be cost-effective. However, since it was uncertain
whether results of modeling studies would be realised in
actual practice, we are therefore undertaking a con-
trolled evaluation of a targeted versus opertunistic
screening approach for cardiovascular risk.This paper presents the protocol for a stepped
wedged cluster randomised controlled trial that aims to
quantify the benefits of targeted case finding of patients
at high risk of CVD over opportunistic assessment and
overcome the challenges of evaluation. The primary hy-
pothesis is that targeted case finding will increase the
rate at which high risk patients are started on treat-
ment. A pilot study, reported in full elsewhere, was
undertaken to determine feasibility and for complete-
ness the findings from this pilot study are briefly sum-
marised before the methodology for the full study are
presented [22].
Pilot study for targeted case finding
In 2005–6 a pilot project of case finding for untreated
high risk patients was implemented in six general prac-
tices in the area covered by Sandwell Primary Care Trust
in the West Midlands, England. In six general practices
cardiovascular risk factor data were extracted from elec-
tronic primary care records of all untreated patients
aged 35 to 74 and high risk patients were identified from
information in their records. Over the course of one
year, in four of the six practices, high risk patients were
sent invitation letters offering assessment by the project
nurse in their own general practice by a project nurse
and if, they were confirmed to be eligible for treatment
were referred to their GP for treatment. Over the same
period, two control general practices were provided with
an equivalent list identifying their high risk patients but
elected to assess patients opportunistically.
Twice as many high-risk patients had their CVD risk
factors assessed in the intervention than control prac-
tices (62% v 28%). Four fifths of those patients who were
assessed, were confirmed to be high risk. Three times
more eligible high-risk patients were started on preventive
treatment in the intervention than in the control practices
(41% v 13%) [22].
Results from the Sandwell pilot suggested that it is
feasible to implement a programme of targeted case
finding and that this might have similar advantages over
opportunistic screening to those estimated from model-
ling studies [19,20]. A further study, in Solihull Care
Trust, also demonstrated support for feasibility of imple-
mentation of the intervention using a prescribing advisor
instead of a nurse.
However, it was not known if these results could be
replicated across a larger number of practices and the
small and non-randomised nature of the evaluation
means that the apparent increase in patients started on
treatment could reflect systematic differences between
the practices rather than effects of the intervention.
There was also little information on the experience of
the case finding programme from the perspective of
patients or of practice staff.
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The evidence of effectiveness of the intervention from
the pilot study, although encouraging, is limited and so
it is important to undertake a robust evaluation of the
programme. If targeted case finding could be demon-
strated to be more effective than opportunistic assess-
ment it could be advocated more widely across primary
care systems. However, both implementation and evalua-
tion presented a number of challenges. First, an efficient
method must be found to identify untreated high risk
patients for invitation. Second, a practical plan was
needed for implementation across a large number of
general practices given limited resources for implemen-
tation. Third, a methodology was needed to evaluate the
effects of targeted case finding given the fact that in both
Sandwell and Solihull the case-finding programmes were
to be implemented in all practices at the same time.
Fourth, an efficient means of data collection needed to
be identified.
Implementation and stepped wedge evaluation
Within Sandwell Primary Care Trust there was support
to continue and expand the targeted case finding project
to include all its practices and within Solihull Care Trust
there was support to expand the project to include all
practices in the northern part of the care trust. However
the number of project nurses/prescribing advisors avail-
able to implement the case finding was limited and itMonth 
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Figure 1 Stepped wedge trial design with different steps of differentwas therefore not possible to offer targeted case finding
to all practices concurrently. It was therefore planned
that the project nurses/prescribing advisors would se-
quentially implement the target case finding in a phased
way across all general practices. Because the unit of
intervention for the case finding programme was a gene-
ral practice, it was neither practical nor acceptable to
randomly allocate individual patients to invitation to a
case finding programme or usual care. However the
phased intervention across general practices provided an
opportunity to evaluate the effects of the case finding
programme on the proportion of high risk patients
started on treatment in practices before and after imple-
mentation of targeted case finding. If the order in which
case finding was implemented in practices could be ran-
domised this would form the basis of a stepped wedged
cluster randomised controlled trial [23].
A stepped wedge cluster randomised controlled trial is a
study design that has been used to evaluate interventions
in health care, social policy and education [24]. They have
mainly been used to evaluate routine implementation and
the earliest published example involved roll out of Hepa-
titis B immunisation across regions of Gambia [25]. In this
type of trial the intervention is implemented in a number
of clusters but the order in which clusters receive the
intervention is random (Figure 1). At the end of the trial
all clusters will have received the intervention. Outcome
data are collected at each step; in other words at each time0 11 12 13 14 15 16 17 18 
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lysis therefore compares data points in the control section
of the wedge (not exposed to the intervention) with those
in the intervention section (exposed to the intervention).
Methods/design
Practice recruitment
By 2008 of 65 practices in Sandwell Primary Care Trust,
case finding had already been completed in 12 (six as
part of the pilot project); in a further 25, case finding
had started or a start date had already been agreed; two
practices did not have available consultation rooms in
the practice building, leaving 26 practices for randomisa-
tion. The total population registered with these practices
was approximately 125,000 and from the pilot study it was
anticipated that 5% (about 6,250) would be untreated high
risk patients.
There were six practices in Solihull Care Trust in
whom the targeted case finding programme could be
implemented. The total population registered in these
practices was 18,938 and it was anticipated that 945
(5%) would be untreated high risk patients.
Therefore overall 32 practices, representing 32 separate
clusters, were included in the study with a combined esti-
mated 7,247 untreated people at high risk of CVD.
Randomisation
Randomisation was stratified by primary care trust. In
Sandwell PCT, after discussion with the case finding
programme manager, it was agreed that 11 practices
were a higher priority for the case finding intervention
and the remaining 15 practices were a lower priority. It
was therefore decided to stratify the practices into two
groups for randomisation: early intervention and late
intervention. A table of random numbers was generated
to determine the order in which practices should receive
the project nurse led intervention in the early interven-
tion group and a second table for practices in the late
intervention group.
The six practices in Solihull were of different charac-
teristics, two were single handed and two were located
very near each other and served similar populations.
They were therefore stratified into three pairs (two single
handed, two similar location and two remaining practices)
for randomisation. A table of random numbers was
generated to determine which of each pair should have
the intervention first and which second.
Inclusion criteria
All patients aged 35 to 74 who were not currently on
the CVD or diabetic registers and who were not cur-
rently receiving antihypertensive or statin treatment (no
prescription within 90 days) were included in theprogramme. From this were selected all those whose
estimated ten-year CVD risk ≥20%.
Practice software systems were used to identify
patients with a ten-year CVD risk ≥20%. In Sandwell
PCT all practices subscribe to Clinical Manager software
manufactured by MSDi [26]. This software produces lists
of patients meeting pre-specified criteria (e.g. diabetic
patients due for a blood pressure measurement). The
manufacturers incorporated an additional module into
the software to calculate ten-year CVD risk for all un-
treated patients without CVD using the Framingham
risk equations [27]. The following method was used to
deal with missing risk factor data. If smoking status was
missing the patient was assumed to be a non smoker; if
blood pressure or cholesterol values were missing a de-
fault value was used, based on the average for an un-
treated person of that age, sex, smoking status and
diabetic status. This followed a previously described
method [28]. In Sandwell PCT this allowed every prac-
tice to produce a list of untreated patients at ≥20%
ten-year CVD risk (high risk patients).
In Solihull PCT practice data was extracted using the
search facility in the electronic patient records and
exported to an Excel spreadsheet. Ten year CVD risk
(high risk patients) was calculated in the spreadsheet
using the same method and patients at ≥20% ten-year
CVD risk (high risk patients) were identified for the
practices.Exclusion criteria
Participating practices reviewed the list of high risk
patients identified and excluded those who had died,
moved practice and or who the GP judged were unsui-
table for CVD prevention (e.g. those with a terminal
illness).Intervention
The intervention in Sandwell was delivered by project
nurses trained in the management of either diabetes or
coronary heart disease. In Solihull prescribing advisors,
trained pharmacists who were licensed to prescribe,
delivered the intervention.
In the intervention practices the project nurse (Sandwell)
or prescribing advisor (Solihull) arranged for a letter along
with an information sheet about the case finding project to
be sent from the GP inviting patients for cardiovascular as-
sessment. The letter specifically mentioned that patients
might be offered lifestyle advice and medication (Additional
file 1 and Additional file 2). The patient was given the time
and date of an appointment for their CVD assessment and
asked to reschedule if this was unsuitable. If they did not at-
tend or reschedule the appointment two further attempts
were made to contact patients either by letter or telephone.
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risk factor assessment, including enquiry about smoking,
measurement of blood pressure, blood tests for fasting
glucose, total cholesterol and HDL cholesterol. Each
patient’s ten-year CVD risk was calculated using the Fra-
mingham equation as recommended in UK guidelines
based on their measured risk factors and their eligibility
for treatment was determined [2,3]. If they were eligible
for antihypertensive or statin treatment the project
nurse/prescribing advisor discussed the risks and bene-
fits of treatment with the patient and the general practi-
tioner was informed so that treatment could be initiated.
If appropriate the patient could also be referred to local
smoking cessation services, for advice on physical activity
or for dietary advice about weight loss.
Patients at highest risk were invited first followed by
those at next highest risk until all high-risk patients
(≥20% ten-year CVD risk) had been invited. The project
nurse (or prescribing advisor) then repeated the process
in the next practice in a sequence determined by the
randomisation. Because the practices varied in size this
meant that the number of weeks spent at each practice
would be expected to vary from one practice to another.
It was anticipated that it would take about 18 months to
complete the implementation of targeted case-finding in
all Sandwell practices and about 12 months in Solihull
practices.
Primary outcomes
Since there is good evidence for the effectiveness of
CVD prevention, it is reasonable to use uptake of treat-
ment as evidence of effectiveness. Prescriptions of anti-
hypertensive drugs or statins are recorded in electronic
primary care records, therefore routine data could be
used to assess outcomes.
The primary outcome is the number of high-risk
patients started on at least one preventive treatment: an
antihypertensive drug or a statin. Antihypertensive drugs
and statins are defined by the chapter codes in the British
National Formulary [29].
Secondary outcomes include the number of patients
who have cardiovascular risk factors assessed (blood
pressure, lipid levels); the number of patients referred to
services for lifestyle advice (smoking cessation services,
advice on physical activity, dietetic advice on weigh loss);
changes cardiovascular risk factors (blood pressure, lipid
levels); cardiovascular events (new diagnoses of angina,
MI, TIA or stroke).
Follow up and data collection
Data extraction will be undertaken as a single data ex-
tract at least one year after targeted case-finding has
been implemented in the last practice. This allows for at
least a year of follow up. The number of untreated high-risk patients who are started on treatment will be
assessed at the start of each step in the stepped wedge
trial. An outline of the data extracted is given in Table 1.
Analysis
The characteristics of the populations served by the GP
practice will be summarised, including, primary care
trust, list size, age of practice population, gender, ethni-
city and practice Index of Multiple Deprivation score.
[30] These characteristics will be summarised by num-
bers and percentages, means and standard deviations or
medians and inter-quartile ranges as appropriate. We
will then report the number of patients excluded in the
study by each of the inclusion criteria (age, CVD status
and medication use), and also the number of patients
meeting the study inclusion criteria.
Fidelity of uptake will be explored by reporting, the
number of patients invited, the number of patients seen
by the nurse/prescribing advisor and the proportion who
were subsequently confirmed to have a CVD risk ≥20%.
The characteristics of the patients included in the
invited population will also be summarised. These char-
acteristics will include gender, age, blood pressure, lipids,
glucose, medication use (at baseline), cardio-vascular
disease, smoking status, Framingham risk score, and
referrals to smoking cessation, physical advice and dietetic
advice services. These characteristics will be sum-
marised by their values at baseline (2008) and will be
compared between those not attending; and for those
attending stratified by whether their calculated risk was
greater than 20%.
The primary aim of the study is to evaluate whether
there is a difference in proportion of eligible patients on
the relevant prescription medication before and after the
practice was exposed to the intervention. In statistical
terms this null-hypothesis (no difference) can be tested
using a mixed logistic regression model with binary out-
come (prescription of the appropriate medication). Im-
portant independent variables to consider are the
clustering effect (i.e. effect of GP practice), calendar time
effect (since the intervention is sequentially rolled-out)
and an indicator of intervention exposure for each prac-
tice at each time point; in an to adjustment for other
characteristics [4]. These models will be fitted using
population averaged models using GEE methods in
STATA, allowing for clustering and adjusting for indivi-
dual level covariates and any cluster level covariates
where available. Population averaged models as opposed
to random effects models (also known as marginal models)
will be used as within the framework of cluster rando-
mised trials, random effects models both lack appropriate
interpretation and might be biased [31]. The covariates to
be included in the adjustment will be pre-specified and will
include practice size and patient level characteristics (age,
Table 1 Data to be extracted from electronic primary care
records at the end of the study




























BNF Chapter 2.2.1 Thiazide and related
diuretics
BNF Chapter 2.2.3 Potassium-sparing
diuretics and other diuretics
BNF Chapter 2.2.4 Potassium-sparing
diuretics with other diuretics
BNF Chapter 2.4 Beta-blockers
BNF Chapter 2.5.1 Vasodilator
antihypertensives
BNF Chapter 2.5.3 Adrenergic neurone
blocking drugs
BNF Chapter 2.5.4 Alpha blockers
BNF Chapter 2.5.2 Centrally acting
antihypertensives
BNF Chapter 2.5.5.1 ACE inhibitors
BNF Chapter 2.5.5.2 ARB-2
BNF Chapter 2.6.2 Calcium-channel
blockers
BNF Chapter 2.8.1 Parenenteral
anticoagulant
BNF Chapter 2.8.2 Oral anticoagulant
BNF Chapter 2.9 Antiplatelet drug
BNF Chapter 2.12 Lipid lowering drug
Over the counter aspirin use
Marshall et al. BMC Public Health 2012, 12:908 Page 6 of 9
http://www.biomedcentral.com/1471-2458/12/908sex, diabetic status, smoking status, blood pressure, total
cholesterol and HDL cholesterol); GP practice will be
included as a random effect; time point as a fixed effect;
and exposure or non-exposure as the main intervention
effect. Null hypotheses for secondary outcomes take a
similar form to that for the primary outcome. Analysis of
the secondary outcomes will take a similar form to that
described for the primary outcome.
The primary outcome will be considered significant at
the 5% level and so 95% confidence intervals (CIs)
reported; whereas secondary outcomes will be deemed
significant at the 1% level (and so 99% CIs reported).
This difference in levels of significance, give more
weight to the primary outcomes. Analysis will be strati-
fied by primary care trust: the analysis of the project
nurse led intervention in Sandwell and the prescribing
advisor led intervention in Solihull will be carried out
separately.Sample size & number of practices
Since the analysis is to be stratified by primary care trust
sample size calculations were also stratified by trust.
However, since this is a pragmatic evaluation the study
has a limited sample size to those practices which agreed
to participate in the evaluation. In the Solihull trust only
6 practices agreed to participate and it was not expected
that this would provide adequate power. We therefore
based power calculations on the Sandwell part of the
study only. In the pilot study approximately 5% to 6% of
registered patients in each practice were found to be
untreated high risk patients. In Sandwell this means we
expect to invite between 6,241 and 7,489 untreated
high-risk patients from a total registered population of
124,820. From this fixed study size, it is possible to esti-
mate the difference that will be detectable (difference
between patients exposed and not exposed to the
intervention in proportion of eligible patients medi-
cated). These patients are spread across 26 clusters,
each with a conservative estimate of average size of
240 (assuming 5% of patients eligible); but with some
variation between practices sizes with coefficient of
variation of 0.74.
The difference detectable depends on the level of
intra-cluster correlation (ICC), the variation in sizes of
practices, and the proportion of patients medicated in
the control arm. Estimates of ICC would ideally come
from other similar studies, but in the absence of such
evidence we are guided by a review of estimates of ICCs
which found that ICC values are typically between 0.02
and 0.1 [32]. The stepped wedge nature of this study
should mean that impact of intra-cluster correlations are
lower than in conventional cluster trials [4], so these
values can be viewed as conservative. The pilot study
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on medication over the course of one year is around 13%.
So, using several different estimates of likely values of
ICCs and current proportions of patients medicated, we
have estimated what values for outcomes post interven-
tion could be detected (all for 80% power, 5% signifi-
cance and coefficient of variation of 0.74). We have used
conventional cluster RCT power calculation methods
since this study is a modification of the conventional
stepped wedge design and so provide conservative esti-
mates [33].
For example, if the current proportion of patients
medicated is about 13%, and values for intra cluster cor-
relation low (ICC of 0.01) then this study would be
powered to detect an increase in proportion of high risk
patients started on treatment to 19% (a relative risk of
1.46); with an ICC of 0.05 the study would detect an in-
crease to 21% (relative risk 1.62); with an ICC of 0.1 the
study would detect an increase to 26% (relative risk
2.00). If however the current proportion of patients
medicated was closer to 20% and the ICC much higher
(say 0.1) then this study would provide 80% power to
detect an increase to 40% (that is almost a 20% absolute
percentage increase).
Economic evaluation
An economic evaluation will also be carried out. Costs
will be imputed from prescribing and consultation rates
determined from data extracts. A Markov model will be
constructed to determine long term impacts on costs and
health outcomes (QALYs) using the effects of treatment in
the short term to determine the long term impact on
QALY life expectancy and health service costs.
Qualitative research
Alongside the trial, qualitative research will explore the
barriers and facilitators to the implementation of the
programme. In combination, the qualitative and quanti-
tative components of the full study will generate know-
ledge not only on the potential value, but also the
feasibility and acceptability, of rolling out the case-
finding intervention more widely in the NHS. Birming-
ham and the Black Country provide the opportunity to
explore attitudes to and experience of primary preven-
tion within an ethnically and economically diverse urban
community. These findings may also be transferable to
other similar programmes for prevention of serious disease
in primary care. Interview data will be collected from the
implementers of the programme, including the research
team, and from patients that have attended.
The aims are:
– To explore the implementation process, using
in-depth interviews, and propose theories aboutwhat implementation configurations need to be in
place for successful implementation.
– To explore the patients’ experience of the
intervention and how it fits into their broader health
beliefs and health behaviours, using subject-
produced photo elicitation[34] (Harper 2002) in the
context of an open-ended interview. This will enable
an appraisal of the acceptability of the intervention
along with insights into barriers and facilitators to
adherence.
Ethical approval
Advice on the need for ethical approval was sought from
the National Research Ethics Service. Implementation of
the targeted case-finding programme was being rolled
out as rapidly as was practical. The order in which the
implementation was being carried out in each practice
had been determined in advance by randomisation. No
additional investigations or measurements were being
undertaken and no patient identifiable data would leave
the NHS. We were therefore advised that this did not
need ethical approval as it was evaluation of a service
development [Additional file 3].
Although interviews with patients and clinical staff for
the qualitative evaluation could also be considered as
part of the service evaluation we sought and obtained
ethical approval from the University of Birmingham ethics
committee for this part of the study [Additional file 4]. In-
formation sheets and consent forms were provided for
interview participants who were clinical staff or patients
[Additional file 5, Additional file 6, Additional file 7 and
Additional file 8].
Discussion
There is very limited published evidence for the bene-
fit of targeted case finding for CVD over opportunistic
case finding. The prevention and early treatment of
CVD, as the biggest killer and a major cause of mor-
bidity in the UK, has the potential to make huge
impacts to the health of populations. We have pre-
sented the design and methods for a stepped wedged
cluster RCT to assess the benefits of systematic case
finding of patients at high risk of CVD over opportunistic
assessments.
There were strong imperatives to implement the car-
diovascular prevention project across all practices due to
a widespread consensus that this type of case finding ap-
proach “made sense” and the benefits of early interven-
tion in CVD and diabetes are well known. In addition
the practices served deprived populations where the bur-
den of cardiovascular disease was relatively high com-
pared to the rest of the country and clinicians felt a
responsibility to give their patients these opportunities
to improve their health. The mandate to implement case
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duct a cluster randomised controlled trial, however the
stepped wedged cluster design allows the process of im-
plementation to be structured in such a way as to ensure
that an evaluation of targeted versus opportunistic case
finding could be undertaken.
The limitations that are present in this study, were
largely as a result of the need to work with the enthusiasm
that existed to implement this approach and evaluate a
real world roll out of this approach in the most robust
way possible. The study was implemented at a time when
the NHS were rolling out health checks in those aged 40
to 74. This might induce contamination, whereby those
practices included in this study might also have rolled
out the NHS health checks. The study also was limited
in its size to those primary care practices which agreed
to participate.
One further limitation of this study is the relatively
small number of clusters included. The MRC guidelines
suggest that a minimum of 10 clusters should be used in
each arm of a cluster randomized trial [35]. In this set-
ting we are limited by the number of GP practices in the
two primary care trusts. However, the stepped wedge na-
ture of this design, in which all practices will eventually
receive the intervention, but the order in which they do
so will be randomised, does provide a more robust de-
sign over the conventional cluster randomized trial and
so may mitigate some of the potential issues surround-
ing the inclusion of what might be considered as a small
number of clusters. This is because within a stepped
wedge design each clusters acts as its own control (dur-
ing the period in which the cluster is not receiving the
intervention) and it has been shown that magnitudes of
intra-cluster correlations are less important [36]. Fur-
thermore, this study is a modification of the common
step-wedge design because after completion of case find-
ing the intervention is not maintained in the clusters
(rather the nurse who delivers the intervention moves to
the next practice). In effect, this probably means a
reduced level of power to detect an effect of the inter-
vention due to contamination of patients not exposed
but nonetheless contributing to the analysis in later
wedges.
Routine data on prescription of antihypertensives and
statins is a pragmatic and easily collected outcome.
However this leaves the study vulnerable to primary non
compliance as not all those who are issued prescriptions
take them.
We hope to be able to determine whether case finding
is more effective and cost effective in achieving higher
rates of uptake of preventative advice and treatment;
whether it results in a reduction in outpatient referrals
and admissions to hospital for CVD related events; and
whether it is acceptable to clinicians and patients.Additional files
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